Farmaceutica Remedia (LTS:0M8I) Change In Receivables: lei0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M8I Farmaceutica Remedia SA LTS:0M8I
61 GF Score
Price lei0.25
GF Value lei0.24
! 11 Warning Signs
View Full Analysis

What is Farmaceutica Remedia Change In Receivables?

Farmaceutica Remedia LTS:0M8I 61 Change In Receivables is lei0.0 Mil as of Jun. 2026. GuruFocus rates LTS:0M8I with a GF Score™ of 61/100 and a GF Value™ of lei0.24. The stock has 11 warning signs investors should review.

Farmaceutica Remedia's change in receivables for the quarter that ended in Jun. 2026 was lei0.0 Mil. It means Farmaceutica Remedia's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Farmaceutica Remedia's change in receivables for the fiscal year that ended in Dec. 2025 was lei0.0 Mil. It means Farmaceutica Remedia's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Farmaceutica Remedia's Accounts Receivable for the quarter that ended in Jun. 2026 was lei196.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Farmaceutica Remedia's Days Sales Outstanding for the three months ended in Jun. 2026 was 101.03.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Farmaceutica Remedia's liquidation value for the three months ended in Jun. 2026 was lei-60.4 Mil.

Farmaceutica Remedia  (LTS:0M8I) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Farmaceutica Remedia's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=196.543/177.518*91
=101.03

2. In Ben Graham's calculation of liquidation value, Farmaceutica Remedia's accounts receivable are only considered to be worth 75% of book value:

Farmaceutica Remedia's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=38.523-271.818+0.75 * 196.543+0.5 * 50.904
=-60.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmaceutica Remedia Change In Receivables Related Terms

Farmaceutica Remedia Change In Receivables Historical Data

* Premium members only.

The historical data trend for Farmaceutica Remedia's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmaceutica Remedia Change In Receivables Chart

Farmaceutica Remedia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Farmaceutica Remedia Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0M8I
61GF Score
Farmaceutica Remedia SA LTS:0M8I
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Farmaceutica Remedia Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of lei0.0 Mil mean?
Farmaceutica Remedia (LTS:0M8I) has a Change In Receivables of lei0.0 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Farmaceutica Remedia and its competitors.
Is Farmaceutica Remedia's Change In Receivables too high?
Farmaceutica Remedia's current Change In Receivables is lei0.0 Mil. Overall, Farmaceutica Remedia has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Change In Receivables compare to MCK and COR?
Farmaceutica Remedia's Change In Receivables of lei0.0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Distribution company?
A good Change In Receivables depends on the Medical Distribution industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current Change In Receivables is lei0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current Change In Receivables of lei0.0 Mil. The stock's GF Value™ is lei0.24, compared to a current price of lei0.25 — trading 4.2% above its estimated fair value. The current Change In Receivables is lei0.0 Mil. Farmaceutica Remedia's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current Change In Receivables is lei0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?

Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued. The current stock price of lei0.25 is trading 4.2% above its estimated GF Value™ of lei0.24.

Key valuation signals for LTS:0M8I:

  • Change In Receivables: lei0.0 Mil
  • GF Value™: lei0.24 vs. price of lei0.25 (4.2% above fair value)
  • GF Score™: 61/100 with 11 warning signs

No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Farmaceutica Remedia Business Description

Other Exchanges RMAH:Romania
Address No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
61GF Score

Get the complete analysis for LTS:0M8I

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.25
Price
lei0.24
GF Value